MedTrace Logo

Chardonnay Marc and Vascular Response

NCT05545865 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-02-18

No results posted yet for this study

Summary

This study aims to obtain data on the potential influence of Vine to Bar product(s) containing Chardonnay marc on cardiometabolic health. These initial studies will inform the design and timing of data collection for future dietary intervention trials that will examine the influence of Chardonnay marc intake on outcomes/biomarkers of both cardiometabolic health and the gut microbiome. This includes collecting data on the potential differences in response to the products based on the unique food matrix for each of the products that will be tested. Moreover, as there is a paucity of data on the influence of cocoa flavanol intake on vascular function beyond 4 hours post intake, the response of the selected outcomes will be assessed after 6 hours of flavanol intake. This is a time point that captures the increased circulating presence of microbial derived flavanol metabolites.

Conditions

Interventions

OTHER

Low Flavanol Cocoa Powder

Measure the response 2 and 6 hours post low flavanol cocoa intake

OTHER

High Flavanol Cocoa Powder

Measure the response 2 and 6 hours post high flavanol cocoa intake

OTHER

Vine to Bar Chocolate - 2 servings

Measure the response 2 and 6 hours post chocolate intake

OTHER

Vine to Bar Chocolate - 1 serving

Measure the response 2 and 6 hours post chocolate intake

OTHER

Vine to Bar Chocolate covered almonds

Measure the response 2 and 6 hours post chocolate covered almond intake

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Carl L Keen · Distinguished Professor Emeritus of Nutrition

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2026-08-24
Completion
2026-08-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05545865 on ClinicalTrials.gov